Perrigo delivered Q3 2025 results reflecting continued headwinds from soft OTC market consumption and strategic portfolio reviews. Revenue fell 4.1% YoY, while adjusted EPS came in at $0.80, down slightly from $0.81. Adjusted operating margin held relatively stable at 16.6%.

Perrigo delivered stable Q2 2025 results with $1.06 billion in revenue and flat organic operating income. Adjusted EPS rose modestly, reflecting lower interest expenses and FX tailwinds. Organic net sales were nearly unchanged due to product divestitures and varied category performance.

Perrigo's first quarter 2025 results showed a slight decline in net sales but significant growth in adjusted EPS and operating income, primarily due to the recovery of the infant formula business and benefits from Project Energize. The company reaffirmed its full-year financial targets despite widening net sales target ranges due to macroeconomic uncertainty.

Perrigo's Q4 2024 revenue declined by 1.6% year-over-year to $1.14 billion due to divested businesses and currency impact, while adjusted EPS increased to $0.93 from $0.86 in the prior year. Adjusted operating income grew by 16% to $194 million, benefiting from cost-saving initiatives. The company's net loss widened to $41 million due to restructuring and litigation-related charges, but strong performance in infant formula sales helped offset declines in other categories.

Perrigo reported a decrease in net sales by 3.2% to $1.1 billion, with organic net sales decreasing by 2.4%. However, the company saw significant growth in adjusted operating income, which increased by 21.3% to $182 million. Adjusted diluted EPS increased by 26.6% to $0.81. The infant formula business is recovering, with net sales growth of 3% compared to the prior year quarter and 58% sequentially.

Perrigo's Q2 2024 net sales declined by 10.7% to $1.1 billion, with organic net sales decreasing by 9.1% due to lower infant formula sales and reduced demand in upper respiratory and pain & sleep aids categories. Adjusted operating income increased by 1.5% to $139 million, and adjusted diluted EPS was $0.53. The company reaffirms its fiscal 2024 adjusted diluted EPS outlook of $2.50-$2.65.

Perrigo's first quarter net sales were $1.1 billion, an 8.4% decrease compared to the prior year. The company's adjusted diluted EPS was $0.29, a 35.6% decrease compared to the prior year, primarily due to the impact of infant formula. The company reaffirms its fiscal 2024 adjusted diluted EPS range outlook of $2.50-$2.65.

Perrigo's Q4 2023 results showed a slight increase in net sales and a significant improvement in adjusted earnings per share. Net sales from continuing operations were a fourth quarter record. The company launched 'Project Energize' to drive sustainable growth.

Perrigo Company plc announced financial results for the third quarter ended September 30, 2023. Net sales increased by 2.2% compared to the prior year quarter, driven by the acquisition of Gateway infant formula facility and favorable foreign currency translation. Adjusted diluted EPS was $0.64, an increase of 14.3% compared to the prior year quarter.

Perrigo's Q2 2023 net sales grew by 6.4% to $1.2 billion, with organic net sales up by 0.8%. The company's reported gross margin improved by 270 basis points to 35.9%, and adjusted gross margin expanded by 220 basis points to 38.7%. Reported EPS was $0.06, while adjusted diluted EPS increased by 46.5% to $0.63. Perrigo reaffirms its fiscal 2023 outlook.

Perrigo Company plc reported a 10.0% increase in net sales to $1.2 billion for the first quarter of fiscal year 2023. Adjusted diluted EPS increased by 35.6% to $0.45. The company reaffirms its fiscal 2023 organic net sales and total net sales growth outlook range of 3.0%-6.0% and 7.0%-11.0%, respectively, versus the prior year, and adjusted diluted EPS range outlook of $2.50-$2.70.

Perrigo reported a 4.6% increase in net sales to $1.2 billion for Q4 2022, with a reported EPS loss of ($0.09) and adjusted diluted EPS of $0.75, a 25.0% increase compared to the prior year quarter. The company achieved a 38.4% adjusted gross margin, a 350 basis points increase compared to the prior year quarter.

Perrigo reported strong third quarter results with net sales of $1.1 billion, a 5.5% increase year-over-year. Adjusted EPS increased by 24.4% to $0.56. The company reiterates its fiscal 2022 organic net sales growth range outlook of 9.0%-10.0% and updates its adjusted EPS range outlook to $2.00-$2.10.

Perrigo reported a strong second quarter with a 14.3% increase in net sales to $1.1 billion, driven by consumer self-care products and the acquisition of HRA Pharma. Despite inflationary pressures and currency translation impacts, the company saw improvements in adjusted gross margin and maintained its full-year outlook.

Perrigo's Q1 2022 net sales reached $1.1 billion, a 6.4% increase year-over-year, with organic net sales growing by 9.7%. Adjusted diluted EPS was $0.33, compared to $0.50 in the prior year. The company raised its fiscal year 2022 net sales growth guidance to 8.5%-9.5% and adjusted EPS guidance to $2.30-$2.40.

Perrigo's fourth quarter net sales grew by 4.9% to $1.1 billion, driven by a strong rebound in demand for cough/cold products. The company's transformation into a focused, consumer-centric Self-Care company is now complete and their focus going forward is on long-term, profitable growth.

Perrigo reported a 4.0% increase in net sales to $1.04 billion in Q3 2021. However, adjusted diluted EPS decreased by 25.0% to $0.45 per diluted share due to lower operating efficiencies, higher materials and freight costs, and product recalls. The company lowered its fiscal 2021 outlook.

Perrigo's Q2 2021 net sales increased by 3.4% to $981 million, driven by growth in most businesses and favorable currency movements, but adjusted EPS decreased by 15.3% to $0.50 due to reinstatement of brand and marketing investments.

Perrigo reported a decrease in net sales and adjusted EPS for Q1 2021, primarily due to pantry loading in the prior year and a weak cough/cold season. However, the company reaffirmed its full-year guidance, citing strong business fundamentals and anticipated improvements in retail traffic and cough/cold incidence.

Perrigo reported a decrease in fourth-quarter consolidated net sales by 2.5% to $1.3 billion, primarily due to lower sales of cough/cold products. The company's reported net loss was $175 million, or $1.29 per diluted share, compared to a net loss of $19 million, or $0.14 per diluted share, in the prior year period. Adjusted diluted EPS was $0.93, a decrease of 12.3% compared to the previous year.

Perrigo reported a 1.3% increase in consolidated net sales for Q3 2020, driven by growth in Consumer Self-Care Americas. However, adjusted EPS decreased by 10.6% due to a charge from the RX albuterol recall. The company reaffirmed its full-year adjusted EPS guidance.

Perrigo Company plc reported a 6.1% increase in consolidated net sales for the second quarter of 2020, reaching $1.2 billion. Adjusted diluted EPS increased by 19.8% to $1.03. The company reaffirmed its fiscal year 2020 adjusted diluted EPS guidance, despite challenges posed by COVID-19 and the divestiture of the Rosemont business.

Perrigo Company plc reported a strong first quarter in 2020, with net sales of $1.3 billion, a 14.2% increase compared to the prior year quarter. The company's performance was positively impacted by a surge in demand for certain products due to consumer and customer behavior surrounding the COVID-19 pandemic, which added an estimated $90 million to $110 million in net sales.

Perrigo reported a 10.7% increase in consolidated net sales to $1.3 billion for Q4 2019, driven by increased demand, the addition of Ranir, and new product sales. Adjusted diluted EPS increased 9.3% to $1.06.